Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) target, is showing promising outcomes in early patient studies. Current research suggests https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/